Five numbers in the abstract
Where each one falls
Where it lands on the map
the abstract, start to end
… with use of PCSK9 antibodies (OR, 0.49 [CI, 0.26 to 0.93]; P = 0.030; heterogeneity P = 0.45; I2 = 0%), and increases in the serum creatine kinase level were reduced (OR, 0.72 [CI, 0.54 to 0.96]; P = 0.026; …
… cholesterol levels (mean difference, -47.49% [95% CI, -69.64% to -25.35%]; P < 0.001] and other atherogenic lipid fractions, and it reduced all-cause mortality (odds ratio [OR], 0.45 [CI, 0.23 to 0.86]; P = 0.015; heterogeneity P = 0.63; I2 = 0%) and cardiovascular mortality (OR, 0.50 [CI, 0.23 to 1.10]; P = 0.084; …
← favours treatmentfavours comparator →
could be chanceCardiovascular events
OR 0.490.26–0.93
Cardiovascular events
−47.49−69.6 to −25.4
Cardiovascular events
OR 0.720.54–0.96
Cardiovascular events
OR 0.450.23–0.86
Cardiovascular events
OR 0.500.23–1.10
PCSK9 inhibitorsCardiovascular events
1 / 3